COPD Guidelines

Understanding the Stages of COPD

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that can range from mild to severe. COPD is also an umbrella term and it includes emphysema and chronic bronchitis. The symptoms and prognosis depend upon the stage of the disease. What people don’t often realize is that there are several stages of COPD.

COPD Guidelines 

There are four stages categorized under the COPD GOLD Guidelines. These stages are part of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) system. The GOLD staging system of classification is the main system used by physicians to describe the severity of COPD.

Stages of COPD are determined through testing. The main test used to determine the stage of COPD is a pulmonary function test (PFT) or spirometry. It measures the amount of air a person can blow out, or exhale forcefully, in one second, called the forced expiratory volume (FEV1).

The GOLD staging system divides emphysema and COPD into four stages. The American Association for Respiratory Care also lists a Stage Zero on their chart, which means a person is at risk though their only symptoms are chronic cough with mucus. 

Stages of COPD

  • Stage I – Stage I is mild COPD. Patients in this stage have a chronic cough and mucus. But they may not even know they have COPD. They may make up the 12 million Americans with undiagnosed COPD.
  • Stage II – Stage II is moderate COPD. Patients may be experiencing more and more shortness of breath, even during everyday activities. This is usually the stage where patients see the physician to have their symptoms checked out.
  • Stage III – Stage III is severe COPD. Patients are having major difficulty with air flow, and their quality of life is compromised.
  • Stage IV – Stage IV is very severe COPD. Patients have severe airflow limitations, and their COPD exacerbations are dangerous. Quality of life usually goes down a lot.

Only a physician can accurately diagnose what stage of COPD you have, and help come up with a treatment plan. COPD is a progressive disease, but its symptoms can be treated and the progression can be slowed.

Treating COPD

The Lung Institute utilizes autologous stem cells, derived from the patient’s own bone marrow and blood. During these procedures, stem cells are extracted, isolated and then immediately introduced back into the body where they then divide and replicate into healthy cells specialized to the damaged tissue. The use of autologous stem cells in transplantation is considered to be more reliable than stem cells from another individual as there is a much lower probability of rejection due to the fact that autologous stem cells are derived from the patient’s own body. All our stem cell procedures have shown anti-inflammatory properties beneficial to patients with lung disease.

Stem cells have the ability to self-renew indefinitely, meaning they have the capability to divide many times and specialize to promote the healing of organs while still sustaining the original undifferentiated cell. Depending on the nature of the patient’s condition and health history, the bone marrow procedure is always performed in conjunction with the venous procedure while the venous procedure may be performed on its own.

If you or a loved one has COPD or other lung disease and want to learn more about treatment options, contact us or call (800) 729-3065.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.